Belite Bio (BLTE) Q3 2026 earnings summary

Executive summary

• FDA accepted the tinlarebant STGD1 NDA for Priority Review, set a Feb. 12, 2027 PDUFA date, and will not convene an advisory committee.

• Regulatory filings advanced in Japan, Singapore, the U.K. and Switzerland; launch preparations include payer engagement and commercial teams.

• Q3 GAAP net loss was $30.3M; quarter-end cash, cash equivalents and U.S. Treasury bills totaled $774M.

Financial highlights

• Q3 R&D was $15.5M ($14.7M excluding share-based compensation) vs. $10.3M ($8.0M); SG&A was $21.4M ($16.3M) vs. $12.7M ($2.1M). GAAP operating expenses were $36.9M; 9M expenses were $104.5M.

• Q3 GAAP net loss was $30.3M, or $0.75/share, vs. $21.7M, or $0.65/share; 9M net loss was $85.6M, or $2.13/share.

• Excluding share-based compensation, Q3 net loss was $24.3M, or $0.60/share, vs. $8.8M; 9M adjusted net loss was $59.7M, or $1.49/share.

• Q3 other income was $6.7M and 9M other income was $18.9M, primarily from interest on deposits and U.S. Treasury securities.

• At Sept. 30, 2026, cash and equivalents were $271.3M and U.S. Treasury bills and notes were $502.7M, totaling $774M vs. $780M at Q2 2026.

Outlook and guidance

• FDA review of the STGD1 NDA is ongoing, with a Feb. 12, 2027 PDUFA date; current cash runway is expected to support potential commercialization and continued pipeline advancement.

• Commercial preparations include early payer and pharmacy benefit manager engagement, with launch readiness contingent on approval; a Japan commercial team is in place and direct marketing is planned if approved.

• PHOENIX, tinlarebant’s geographic atrophy trial, is expected to undergo an interim analysis; the GA interim-analysis design is unconfirmed and planned after the Feb. 2027 PDUFA.

• A pediatric PIP study at Moorfields Eye Hospital is expected to start before year-end 2026.